UBS Global Healthcare Conference - INTEGRA LIFESCIENCES HOLDINGS CORP

Explicit Guidance:

• FY2025 Free Cash Flow (FCF): Projected to reach $130–$140 million, a significant recovery from the $25 million in FY2024 and $30 million decline in FY2025 prior to this projection.
• FY2025 Earnings Per Share (EPS): Expected to grow approximately 5%, reversing double-digit declines seen in the prior two years.
• FY2025 Gross Margin & EBITDA: Projected to remain flat year-over-year; however, this is noted as a stabilization following multi-year declines in both metrics.
• FY2025 Q4 Impact (Cincinnati Flood): Forecasted revenue headwind of $15–$20 million, primarily driven by the Mayfield product line lacking secondary supply sources and inventory.
• Price Increases: Management expects to capture an average of ~1% in pricing annually.

Business-Segment Outlook:

• Specialty Surgery (Neurosurgery): Normalized growth expected to run 3.5%–4% (Q3 6.5% growth included a $7M flood headwind and favorable comps). Growth is driven by stable, non-elective procedure volumes and maintained market share (#1 or #2 in most sub-segments).
• Specialty Surgery (International): International business grew in high single digits in Q3, demonstrating demand recovery once supply availability is restored.
• Tissue Reconstruction (PrimaMatrix): Revenue recovery tracking at >50% of pre-recall levels as of Q3 following Q4 2025 relaunch; intended to drive portfolio-based growth across 2026–2027.
• Tissue Reconstruction (Integra Skin): Q3 saw sequential growth but missed internal forecasts due to past supply constraints on larger sizes and competitive share loss; share reclamation is expected to take longer than anticipated.
• Product Relaunches & Portfolio Expansion:
  • Surgimen: Expecting to relaunch 510(k) version soon and pursue PMA for implant-based breast reconstruction with an expanded label, targeting 2027 approval.
  • Durazor (DuraZorb): Actively pursuing a PMA for implant-based breast reconstruction following the Surgimen approval.
  • Final Product Recovery: Expectation to bring the final two recalled products back to the market in 2027.

Market and Competitive Outlook:

• Market Consolidation: Anticipated consolidation in the wound reconstruction market as smaller competitors with insufficient clinical evidence exit due to margin pressures from fixed reimbursement rates (e.g., $127/sq cm).
• Competitive Positioning: Integra leverages its position as a #1 or #2 player in niche spaces with strong clinical evidence and surgeon relationships to resist displacement by larger med-tech conglomerates who may deprioritize niche categories.
• Share Gains: Expecting to regain share lost during Integra Skin supply constraints through improved reliability and educational campaigns on portfolio differentiation (e.g., PrimaMatrix vs. Integra Skin).
• Pricing Environment: No margin impact from recent reimbursement rate changes as Integra is already priced in line with fixed rates; competitors are facing margin compression and higher wastage due to lack of size flexibility.

Macro / Industry Outlook:

• Procedure Volumes: Demand remains stable and durable due to the critical nature of neurosurgery and tissue reconstruction procedures (non-elective).
• Regulatory/Reimbursement Headwinds: Monitoring VBP (Value-Based Procurement) implementation in China moving from province-level to nationalistic approaches; observing potential pressures from CMS reimbursement and ACA subsidy reforms, though material impact currently limited.
• Cost Pressures: Identifying wages, salaries, and material costs (components) as primary inflation drivers, with oil/freight as secondary factors.
• Strategic Levers: Mitigating macro pressures through cost efficiencies rather than aggressive pricing; cost efficiencies are viewed as the primary offset to input inflation.

Strategic Initiatives:

• Supply Chain Remediation: Full recovery of the Cincinnati manufacturing facility, specifically the Mayfield line, is projected for the mid-2027 timeframe due to specialized equipment lead times.
• Commercial Restructuring: Chief Commercial Officer (CCO) role established to consolidate commercial/contracting activities, aiming to leverage enterprise scale for GPO negotiations and supply chain assistance.
• International Expansion (Offense): Resuming "going on offense" strategy in international markets (e.g., China) to deepen penetration beyond Tier 1 hospitals and target high-single-digit growth rates previously achieved.
• Capital Structure: Debt refinancing completed to extend maturities beyond 2027; 75% of capital structure is fixed through 2027, providing flexibility for M&A and innovation.
• Innovation Investment: Continued investment in catheters, tissue ablation, and tissue reconstruction innovation, prioritized by ROI, timeliness (PMA pathways), and enterprise contribution.

Risks and Headwinds to Outlook:

• Cincinnati Flood Recovery: The path to full operational capacity for the Mayfield line remains uncertain; delays beyond mid-2027 could impact revenue.
• Supply Chain Disruption: History of protracted outages has necessitated rebuilding trust; any future disruptions could allow competitors to gain ground, particularly in fragmented markets.
• Competitive Infiltration: During the Integra Skin supply gap, new competitors entered the market; reclaiming this share is proving more difficult than originally forecasted.
• Macro Pressures: Potential for increased material inflation, labor cost increases, tariffs, and interest rate volatility (though mitigated by fixed-rate debt).
• Reimbursement & Regulation: Uncertainty regarding government payer pressure (US and China) and evolving healthcare spending outlooks.

Management Tone on the Future:

• Confidence Level: High confidence in the "turnaround" trajectory, citing the elimination of significant supply interruptions and product recalls over the last three years.
• Narrative Shift: Transitioning from "fixing broken operations" to "going on offense" commercially; management believes the execution discount is warranted but expects to eliminate it as progress becomes visible.
• Cyclical View: Management frames the current period as the bottom of the cost/remediation curve, with a "nice runway" for durable, profitable growth ahead as efficiencies kick in and capacity returns.

Miscellaneous:

• CFO Commentary: CFO noted a shift in investor focus from remediation costs to growth opportunities, highlighting that the "execution discount" is a key target to remove.
• China Manufacturing: Operating a facility in China to mitigate tariff headwinds; awaiting approval to sell products manufactured locally to support market access despite VBP pressures.